Avid Bioservices Inc (CDMO)

[RRdog]

A couple of guesses:

I think this message board is being way to negative. Sometimes a small product advantage translates into an enormous economic advantage especially for small biotech companies.

It is not only the FDA--which from our discussions appears to be clearly looking for alternatives (to Avastin for example). Supposing PPHM bavi presents a 10% efficacy advantage and an 80% side effect advantage with a different MOA. The FDA should like that but, the oncologists in the field that have to treat these human beings with the problem should absolutely love it. Ergo, from a marketing perspective a small edge could be enormous.

Garnick is saying that from his conversations with the FDA that things are A plus and he has been directed as to what path to proceed and he is on that path.

Second guess re technicals: It has historically seemed IMO that Lytle/PPHM sells as much ATM as he needs into the quarter and annual close to keep his cash balance neutral or slightly rising relative to the comparable quarter and year. After the quarter closes by calendar and prior to the cc very little ATM sold historically. ATM generally starts again several weeks after the cc. IMO I would look for technical strength if PPHM stock gets above $1.90/ sh in short term.

I agree with other posters that lament the following:
1. No smarter financing than a self defeating ATM
2. No Partnering
3. No BOD expansion to correct lack of connectivity to national or intl biotech world, to senior financial world, to govt procurement.

Regards,
RRdog